About Molecular Partners
Molecular Partners is a company based in Zurich (Switzerland) founded in 2004. It operates as a HealthTech. Molecular Partners has raised $59.94 million across 3 funding rounds from investors including Index Ventures, Johnson & Johnson Innovation – JJDC and BB Biotech Ventures. The company has 174 employees as of December 31, 2024. Molecular Partners offers products and services including DARPin Therapeutics, MP0533, MP0712, and MP0317. Molecular Partners operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, Adaptive Biotechnologies, Revolution Medicines and Blueprint Medicines, among others.
- Headquarter Zurich, Switzerland
- Employees 174 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Molecular Partners Ag
-
Annual Revenue
$5.49 M (USD)-29.38as on Dec 31, 2024
-
Net Profit
-$59.65 M (USD)12.81as on Dec 31, 2024
-
EBITDA
-$64.96 M (USD)-0.27as on Dec 31, 2024
-
Total Equity Funding
$59.94 M (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
Index Ventures
& 4 more
-
Employee Count
174
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Molecular Partners
Molecular Partners is a publicly listed company on the SIX with ticker symbol MOLN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Molecular Partners
Molecular Partners offers a comprehensive portfolio of products and services, including DARPin Therapeutics, MP0533, MP0712, and MP0317.
Innovative therapies are developed using DARPin platform technology.
Tetra-specific T cell engager is designed for AML.
Radio DARPin Therapy is targeted at DLL3 protein.
Multispecific DARPin is developed for tumor-localized activation.
People of Molecular Partners
Unlock access to complete
Unlock access to complete
Funding Insights of Molecular Partners
Molecular Partners has successfully raised a total of $59.94M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Molecular Partners
Molecular Partners has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Index Ventures, Johnson & Johnson Innovation – JJDC and BB Biotech Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology startups and entrepreneurs.
|
Locked | Locked | Locked | |
|
Venture capital firm backed by Johnson & Johnson
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Molecular Partners
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Molecular Partners
Investment portfolio details for Molecular Partners
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Molecular Partners
Detailed financials for Molecular Partners
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Molecular Partners Comparisons
Peer comparison for Molecular Partners
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Molecular Partners
Molecular Partners operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, Adaptive Biotechnologies, Revolution Medicines and Blueprint Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
Detailed competitors of Molecular Partners
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Molecular Partners
Complete news archive for Molecular Partners
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Molecular Partners
Molecular Partners was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Molecular Partners is headquartered in Zurich, Switzerland.
Molecular Partners is a funded company, having raised a total of $59.94M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Molecular Partners is 174.
Annual revenue of Molecular Partners is $5.49M as on Dec 31, 2024.
Molecular Partners is engaged in the development of innovative DARPin therapeutics targeting cancer and other serious diseases. The company operates within the biotechnology sector, focusing on solutions like radiopharmaceuticals, immune cell engagers, and multispecific therapies. Programs such as MP0533 for AML, MP0712 for Radio DARPin Therapy, and MP0317 for solid tumors are being advanced. Platforms like Switch-DARPin for conditional immune activation are also utilized to address unmet medical needs in oncology.
Molecular Partners's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
Molecular Partners offers DARPin Therapeutics, MP0533, MP0712, and MP0317.
Yes, Molecular Partners is publicly traded on SIX under the ticker symbol MOLN.
Molecular Partners has 5 investors. Key investors include Index Ventures, Johnson & Johnson Innovation – JJDC, BB Biotech Ventures, Endeavour Vision, and EW Healthcare Partners.
The ticker symbol of Molecular Partners is MOLN on SIX.